Publikationen im NUM

Niemeyer D, Schroeder S, Friedmann K, Weege F, Trimpert J, Richter A, Stenzel S, Jansen J, Emanuel J, Kazmierski J, Pott F, Jeworowski LM, Olmer R, Jaboreck M, Tenner B, Papies J, Heinze J, Walper F, Schmidt ML, Heinemann N, Möncke-Buchner E, Veith T, Baumgardt M, Hoffmann K, Widera M, Thao TTN, Balázs A, Schulze J, Mache C, Morkel M, Ciesek S, Hanitsch LG, Mall MA, Hocke AC, Thiel V, Osterrieder K, Wolff T, Martin U, Corman VM, Müller MA, Goffinet C, Drosten C. Post-entry, spike-dependent replication advantage of B.1.1.7 and B.1.617.2 over B.1 SARS-CoV-2 in an ACE2-deficient human lung cell line. 2021;      [DOI] 

Niemeyer D, Schroeder S, Friedmann K, Weege F, Trimpert J, Richter ea. Post-entry, spike-dependent replication advantage of B.1.1.7 and B.1.617.2 over B.1 SARS-CoV-2 in an ACE2-deficient human lung cell line. bioRxiv. 2021;      [DOI] 

Heinrich F, Meißner K, Langenwalder F, Püschel K, Nörz D, Hoffmann A, Lütgehetmann M, Aepfelbacher M, Bibiza-Freiwald E, Pfefferle S, Heinemann A. Postmortem stability of SARS-CoV-2 in nasopharyngeal mucosa. Emerg Infect Dis. 2021; 27(1):329-331.      [DOI] 

Boor P, Eichhorn P, Hartmann A, Lax SF, Märkl B, Menter T, Skok K, Slotta-Huspenina J, Stillfried S, Tzankov A, Weirich G. Praktische Aspekte von COVID-19-Obduktionen [Practical aspects of COVID-19 autopsies]. Pathologe. 2021; 42(2):197-207.

Casagrande M, Fitzek A, Spitzer MS, Püschel K, Glatzel M, Krasemann S, Nörz D, Lütgehetmann M, Pfefferle S, Schultheiss M. Presence of SARS-CoV-2 RNA in the cornea of viremic patients with COVID-19. JAMA Ophthalmol. 2021;      [DOI] 

Oestreich M, Chen D, Schultze JL, Fritz M, Becker M. Privacy considerations for sharing genomics data. EXCLI journal. 2021; 201243–1260.      [DOI] 

Weinberger T, Steffen J, Osterman A, et al . Prospective longitudinal serosurvey of healthcare workers in the first wave of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) pandemic in a quaternary care hospital in Munich, Germany. Clin Infect Dis. 2021; 73(9):      [DOI] 

Fitzek A, Schädler J, Dietz E, Ron A, Gerling M, Kammal A, Lohner L, Falck C, Möbius D, Goebels H, Gerberding A, Schröder A, Sperhake J, Klein A, Fröb D, Mushumba H, Wilmes S, Anders S, Kniep I, Heinrich F, Langenwalder F, Meißner K, Lange P, Zapf A, Püschel K, Heinemann A, Glatzel M, Matschke J, Aepfelbacher M, Lütgehetmann M, Steurer S, Thorns C, Edler C, Ondruschka B. Prospective postmortem evaluation of 735 consecutive SARS-CoV-2-associated death cases. Sci Rep. 2021 Sep.; 11(1):19342.      [DOI] 

Lapuente D, Fuchs J, Willar J, et al . Protective mucosal immunity against SARS-CoV-2 after heterologous systemic prime-mucosal boost immunization. Nat Commun. 2021; 12(1):      [DOI]      [Datei] 

Oberste M, Pusch LM, Roth R, et al . Protocol of the Cologne Corona Surveillance (CoCoS) study: A prospective population-based cohort study. BMC Public Health. 2021; 21(1):      [DOI] 

Schwartz J, others . Psychische Belastung des Intensivpersonals: Kommunikationsseminare helfen. Deutsches Ärzteblatt. 2021; 118(50):

Röthke N, Wollschläger D, Kunzler AM, Rohde A, Molter S, Bodenstein M, Reif A, Walter H, Lieb K, Tüscher O. Psychische Belastung, Resilienz und Absentismusneigung bei Gesundheitspersonal in Deutschland während der ersten COVID-19-Pandemiewelle im Frühjahr 2020. Der Nervenarzt. 2021; 92(6):579—590.      [DOI] 

Veer IM, Riepenhausen A, Zerban M, Wackerhagen C, Puhlmann LMC, Engen H, Köber G, Bögemann SA, Weermeijer J, Uściłko A, Mor N, Marciniak MA, Askelund AD, Al-Kamel A, Ayash S, Barsuola G, Bartkute-Norkuniene V, Battaglia S, Bobko Y, others . Psycho-social factors associated with mental resilience in the Corona lockdown. Translational Psychiatry. 2021; 11(1):1—11.      [DOI]      [Datei] 

Morawa E, Schug C, Geiser F, Beschoner P, Jerg-Bretzke L, Albus C, Weidner K, Hiebel N, Borho A, Erim Y. Psychosocial burden and working conditions during the COVID-19 pandemic in Germany: The VOICE survey among 3678 health care workers in hospitals. Journal of Psychosomatic Research. 2021; 144110415.      [DOI] 

Jerg-Bretzke L, Kempf M, Jarczok MN, Weimer K, Hirning C, Gündel H, Erim Y, Morawa E, Geiser F, Hiebel N, Weidner K, Albus C, Beschoner P. Psychosocial Impact of the COVID-19 Pandemic on Healthcare Workers and Initial Areas of Action for Intervention and Prevention—The egePan/VOICE Study. International Journal of Environmental Research and Public Health. 2021; 18(19):10531.      [DOI] 

Bucher A, Kleesiek J, Kuhl CK, Antoch G, others . RACOON: A nationwide radiological infrastructure of German University Radiologies for collaborative imaging research on COVID-19. Conference of the Radiological Society of North America. 2021;

Denzler A, Jacobs ML, Witte V, et al . Rapid comparative evaluation of SARS-CoV-2 rapid point-of-care antigen tests. MedRxiv. 2021;      [DOI]      [Datei] 

Kluge S, Malin JJ, Fichtner F, Müller OJ, Skoetz N, Karagiannidis C. Recommendations on the In-Hospital Treatment of Patients With COVID-19. Dtsch Arztebl Int. 2021;      [DOI] 

Wagner KI, et al . Recruitment of highly cytotoxic CD8+ T cell receptors in mild SARS-CoV-2 infection. Cell reports. 2021; 35110214.      [DOI] 

Bauer S, Contreras S, Dehning J, Linden M, Iftekhar E, Mohr SB, Olivera-Nappa A, Priesemann V. Relaxing restrictions at the pace of vaccination increases freedom and guards against further COVID-19 waves. PLOS Computational Biology. 2021; 17(9):e1009288.      [DOI] 

Thole D, Ole Diesterhöft T, Vogel S, Greve M, Bauer E, Strathmann S, Elsner C, Kolbe N, Krefting D. Relevant Aspects for Sustainable Open Source Pandemic Apps and Platform Deployment with Focus on Community Building. Stud Health Technol Inform. 2021; 283186—193.      [DOI] 

Ansems K, Grundeis F, Dahms K, Mikolajewska A, Thieme V, Piechotta V, Metzendorf M, Stegemann M, Benstoem C, Fichtner F. Remdesivir for the treatment of COVID‐19. Cochrane Database of Systematic Reviews. 2021; 2021(8):CD014962.      [DOI] 

Wurzer D, Spielhagen P, Siegmann A, Gercekcioglu A, Gorgass J, Henze S, Kolar Y, Koneberg F, Kukkonen S, McGowan H, Schmid-Eisinger S, Steger A, Dommasch M, Haase HU, Müller A, Martens E, Haller B, Huster KM, Schmidt G. Remote monitoring of COVID-19 positive high-risk patients in domestic isolation: A feasibility study. PLOS ONE. 2021; 16(9):e0257095.      [DOI]      [Datei] 

Graf S, Engelmann L, Wölfler O, others . Reopening the Bavarian State Opera Safely: Hygiene Strategies and Incidence of COVID-19 in Artistic Staff During Theater Season 2020/2021. Journal of Voice. 2021;      [DOI]      [Datei] 

Salholz-Hillel M, Grabitz P, Pugh-Jones M, Strech D, DeVito NJ. Results availability and timeliness of registered COVID-19 clinical trials: interim cross-sectional results from the DIRECCT study. BMJ Open. 2021; 11(11):e053096.      [DOI] 

Nordsiek F, Bodenschatz E, Bagheri G, et al . Risk assessment for airborne disease transmission by poly-pathogen aerosols. PLOS ONE. 2021;      [DOI] 

Wunsch M, Aschemeier D, Hegera E, et al . Safe and effective pool testing for SARS-CoV-2 detection. J Clin Virol. 2021; 145      [DOI] 

Reis S, Popp M, Schmid B, Stegemann M, Metzendorf M, Kranke P, Meybohm P, Weibel S. Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis. J Clin Med. 2021; 11(1):57.      [DOI] 

Hillus D, et al . Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. The Lancet Respiratory Medicine. 2021;      [DOI] 

Möckel M, Corman VM, Stegemann MS, et al . SARS-CoV-2 antigen rapid immunoassay for diagnosis of COVID-19 in the emergency department. Biomarker. 2021; 26(3):      [DOI] 

Deinhardt-Emmer S, Bottcher S, Haring C, Giebeler L, Henke A, Zell ea. SARS-CoV-2 causes severe epithelial inflammation and barrier dysfunction. J Virol. 2021;

Wendisch D, Dietrich O, Mari T, Stillfried S, Ibarra I, Mittermaier M, Mache C, Chua R, Knoll R, Timm S, others . SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021; 184(26):6243—6261.e27.      [DOI] 

Wendisch D, Dietrich O, Mari T, Stillfried S, Ibarra IL, Mittermaier ea. SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021; 1846243—6261.e6227.      [DOI] 

Wendisch D, et al . SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021; 1846243-6261.e27.      [DOI] 

Wendisch D, Dietrich O, Mari T, et al . SARS-CoV-2 infection triggers profibrotic macrophage responses and lung fibrosis. Cell. 2021;      [DOI] 

Jansen J, Reimer K, Nagai J, et al . SARS-CoV-2 infects the human kidney and drives fibrosis in kidney organoids. Cell Stem Cell. 2021;      [DOI] 

Hoffmann M, et al . SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization. Cell Reports. 2021; 35109017.      [DOI] 

Malin JJ, et al . SARS-CoV-2 neutralizing antibody treatment in COVID-19 patients with immunodeficiency due to B-cell non-Hodgkin lymphoma. Blood advances. 2021;      [DOI] 

Schwarz T, et al . SARS-CoV-2 Proteome-Wide Analysis Revealed Significant Epitope Signatures in COVID-19 Patients. Frontiers in immunology. 2021; 12629185.      [DOI] 

Stillfried S, Villwock S, Bülow RD, Djudjaj S, Buhl EM, Maurer A, Ortiz-Brüchle N, Celec P, Klinkhammer BM, Wong DW, Cacchi C, Braunschweig T, Knüchel-Clarke R, Dahl E, Boor P. SARS-CoV-2 RNA screening in routine pathology specimens. Microb Biotechnol. 2021 Jul.; 14(4):1627-1641.      [DOI] 

Heinemann S, Bludau A, Kaba H, et al . SARS-CoV-2 surveillance and testing: results of a survey from the Network of University Hospitals (NUM), B-FAST. GMS Hyg Infect Control. 2021; 16      [DOI] 

Heinemann S, Bludau A, Kaba H, Knolle P, Grundmann H, Scheithauer S. SARS-CoV-2 surveillance and testing: results of a survey from the Network of University Hospitals (NUM), B-FAST. GMS hygiene and infection control. 2021; 16Doc31.      [DOI] 

Hoffmann M, et al . SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. Cell Reports. 2021; 36109415.      [DOI] 

Hoffmann M, et al . SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021; 1842384-2393.e12.      [DOI] 

Lohner L, Fröb D, Edler C, Schröder AS, Dietz E, Ondruschka B. SARS-CoV-2-assoziierte Todesfälle von erwachsenen Personen bis 50 Jahre: Eine retrospektive Auswertung der COVID-19-assoziierten Todesfälle im Jahr 2020 im Institut für Rechtsmedizin Hamburg, Deutschland [SARS-CoV-2-associated deaths in adult persons up to 50 years of age]. Rechtsmedizin (Berl). 2021; 1-9.

Gassen N, Papies J, Bajaj T, Emanuel J, Dethloff F, Chua ea. SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals. Nat Commun. 2021; 123818.

Kreuzberger N, et al . SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database of Systematic Reviews. 2021; 9CD013825.      [DOI] 

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021; 9(9):CD013825.      [DOI] 

Hirsch C, et al . SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19. Cochrane Database of Systematic Reviews. 2021;      [DOI] 

Schmidt KG, et al . SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses. Frontiers in immunology. 2021; 12627568.      [DOI]